Equity Overview
Price & Market Data
Price: $0.205
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $66,811,312
Volume: 0
Performance Metrics
1 Week: -10.69%
1 Month: -25.57%
3 Months: -5.71%
6 Months: -15.03%
1 Year: -86.36%
YTD: -5.71%
Company Details
Employees: 139
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Norway
Details
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.